Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

[The role of ramipril in the therapy of diabetic nephropathy].

Dézsi CA.

Orv Hetil. 2014 Feb 16;155(7):263-9. doi: 10.1556/OH.2014.29827. Review. Hungarian.

PMID:
24509355
2.
3.

Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension.

Gupta S, Chattopadhyaya I, Agrawal BK, Sehajpal PK, Goel RK.

J Postgrad Med. 2015 Jan-Mar;61(1):21-6. doi: 10.4103/0022-3859.147028.

4.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
6.

Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.

Tschöpe C, Seidl U, Reinecke A, Riester U, Graf K, Schultheiss HP, Hilgenfeldt U, Unger T.

Int Immunopharmacol. 2003 Mar;3(3):335-44.

PMID:
12639811
7.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
8.
9.

Angiotensin blockade in type 2 diabetic renal disease.

Ruilope LM, Luño J.

Kidney Int Suppl. 2002 Dec;(82):S61-3. Review.

10.

Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.

Thallas-Bonke V, Coughlan MT, Bach LA, Cooper ME, Forbes JM.

Am J Nephrol. 2010;32(1):73-82. doi: 10.1159/000314924. Epub 2010 Jun 11.

PMID:
20551625
11.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
12.

Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).

Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H.

Hypertens Res. 2013 Dec;36(12):1051-9. doi: 10.1038/hr.2013.86. Epub 2013 Sep 12.

13.

[Prediction, screening and treatment of renal complications of diabetes].

Marre M, Larger E.

Rev Prat. 2001 Oct 15;51(16):1769-75. French.

PMID:
11795120
14.

Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.

Zhang MZ, Wang S, Yang S, Yang H, Fan X, Takahashi T, Harris RC.

Am J Physiol Renal Physiol. 2012 Feb 15;302(4):F433-8. doi: 10.1152/ajprenal.00292.2011. Epub 2011 Nov 23.

15.

Current update in the management of diabetic nephropathy.

Van Buren PN, Toto R.

Curr Diabetes Rev. 2013 Jan 1;9(1):62-77. Review.

PMID:
23167665
16.

[ACE inhibitors for diabetic patients. passed the test on the heart and kidneys].

[No authors listed]

MMW Fortschr Med. 2002 Oct 31;144(44):53. German. No abstract available.

PMID:
12494601
17.

[Control of arterial pressure in diabetic nephropathy].

Luño J, García de Vinuesa S.

Nefrologia. 2001 May-Jun;21(3):240-5. Review. Spanish. No abstract available.

18.

Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.

Eberhard R, Dikow R.

Ann Med. 2002;34(7-8):507-13. Review.

PMID:
12553490

Supplemental Content

Support Center